The loss of sensitivity of tumor cells to TNF could be mediated by TRAF2, given that inhibition of TRAF2 in tumor cells re-sensitizes them to TNF in vitro and improves the efficacy of ICB in mice bearing ICB-resistant tumors (Vredevoogd et al., 2019). The gene discussed is TNF; the disease is neoplasm.